Chromophobe renal cell carcinoma
Prepared with OnCo (onco.cc/prep/chromophobe-rcc/). Orientation, not medical advice; your team knows your case.
My details
What I know, what is unclear, changes to discuss
Saved in this browserMy questions
13 on the sheet- 1.What is my exact diagnosis, stage, and grade, and which tests established them?
- 2.Which biomarkers have been tested on my tumour (for example Multiple whole-chromosome losses, TP53 and PTEN mutations, CK7 and KIT positive, distinguishing it from oncocytoma, Germline FLCN testing when syndromic features are present), and what were the results?
- 3.Which subtype is my cancer, and does that change the recommended treatment?
- 4.Is germline (inherited) genetic testing recommended for me or my family?
- 5.For my situation (localised), which of the standard options do you recommend and why?
- 6.For my situation (metastatic), which of the standard options do you recommend and why?
- 7.Am I a candidate for Sunitinib, Cabozantinib, Everolimus or related drugs, and what side effects should I expect?
- 8.For my situation (birt-hogg-dube syndrome), which of the standard options do you recommend and why?
- 9.Are there clinical trials I could join, for example of Lenvatinib, Everolimus?
- 10.Would a second opinion at a high-volume centre change anything, and can you help arrange it?
- 11.What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?
- 12.I read that “No randomised trial has ever been run in chromophobe cancer”. How does that affect my plan?
- 13.I read that “Immunotherapy rarely works and the reason is not understood”. How does that affect my plan?
Tests and results to bring
Biomarker results to ask for: Multiple whole-chromosome losses, TP53 and PTEN mutations (poor outlook), CK7 and KIT positive, distinguishing it from oncocytoma, Germline FLCN testing when syndromic features are present.
Scans and tests linked to this cancer: Active surveillance.
Bring copies of scan reports, pathology and blood results, and a list of every medicine and supplement.
The treatments I may be offered
- Localised: Partial nephrectomy or ablation; active surveillance for small tumours; no adjuvant therapy. (Thermal ablation (RFA, microwave, cryo), Active surveillance)
- Metastatic: Sunitinib, cabozantinib, everolimus or lenvatinib plus everolimus; immunotherapy has low response rates outside sarcomatoid disease; trials preferred. (Sunitinib, Cabozantinib, Everolimus, Lenvatinib)
- Birt-Hogg-Dube syndrome: Kidney surveillance with MRI, nephron-sparing surgery at 3 cm, and genetic counselling. (Renal cell carcinoma)
From the standard of care recorded for this cancer; which apply depends on your stage and biomarkers. Ask which the team recommends and why.